de novo

ventures

"of new" 

venture capital

BUILDING GREAT TECHNOLOGY COMPANIES

100%

All of our portfolio companies are thriving and growing

>4x

Return on investments 

 
 
 

LATEST
INVESTMENTS

CAPSULASER
Selective laser capsulotomy

Enhancing sight

ALPHAEON CREDIT

 

Enhancing patient financing

Evolus
NASDAQ: EOLS 
Cosmetic Injectable Neurotoxin 

Enhancing beauty

OUR ETHOS

CUSTOMER
FOCUS

We never forget that our portfolio companies are here to serve their customers and always be guided by their moral compass.

PRIDE IN EXCELLENCE

We set a high bar and sweat the details. Holding ourselves accountable and always striving for excellence through continual improvement.

WINNING CULTURE

We support our companies until they succeed.

We are focused on:

winning products

+ winning teams

= winning results 

 
 

PORTFOLIO

evolus.JPG

IPO(NASDAQ): EOLS

Zelegent logo.JPG
Aeon logo.JPG
describe.JPG

Acquired by Merz

OPTIMEDICA

PRECISIONLIGHT

Sold twice:

+ Cataract division acquired by Abbot now part of J&J Vision

+ Retina division acquired by Topcon 

Acquired by Allegan

now part of Abbvie

OUR DNA

de novo ventures has a long history of world-class entrepreneur expertise. All the de novo team have built great companies as executive management, upon successful exit the CEOs and founders of our portfolio companies are invited to be part of de novo ventures. This brings real-world experience to creating the "next" great technology companies.

Dave Mordaunt PhD

Managing Director

 

© 2020 de novo ventures